Bristol Myers Squibb Exercises Option to Develop Exscientia's AI-designed, Immune-modulating Drug Candidate
First candidate in multi-target collaboration to reach in-license milestone BMS to take responsibility for clinical and commercial development Exscientia receives $20 million option exercise